International Journal of
Molecular Sciences

MDPI

Correction

Correction: Funk et al. Criticality of Surface Characteristics of Intravenous Iron-Carbohydrate Nanoparticle Complexes: Implications for Pharmacokinetics and Pharmacodynamics. *Int. J. Mol. Sci.* 2022, *23*, 2140

Felix Funk, Beat Flühmann and Amy E. Barton *

Vifor Pharma Management Ltd., Flughofstrasse 61, CH-8152 Glattbrugg, Switzerland
* Correspondence: amy.barton@viforpharma.com; Tel.: +41-58-851-8000

The authors wish to make the following corrections to this paper [1]:

In the original publication, there were wrong reference citations in paragraph 7 of Section 2.2 and Table 4 as published.

In Section 2.2, paragraph 7, "Ferumoxytol contains 30 mg of iron/mL. The complex is an iron oxide coated with polyglucose sorbitol carboxymethylether. The chemical formula of ferumoxytol is $Fe_{5874}O_{8752}$-$C_{11719}H_{18682}O_{9933}Na_{414}$ [24]" should be replaced with "Ferumoxytol contains 30 mg of iron/mL. The complex is an iron oxide coated with polyglucose sorbitol carboxymethylether [25]. The chemical formula of ferumoxytol is $Fe_{5874}O_{8752}$-$C_{11719}H_{18682}O_{9933}Na_{414}$ [26]".

In Table 4, the reference numbers did not correspond with the correct numbers in the reference list. The corrected Table 4 appears below:

The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Citation: Funk, F.; Flühmann, B.; Barton, A.E. Correction: Funk et al. Criticality of Surface Characteristics of Intravenous Iron-Carbohydrate Nanoparticle Complexes: IMPLICATIONS for Pharmacokinetics and Pharmacodynamics. *Int. J. Mol. Sci.* 2022, *23*, 2140. *Int. J. Mol. Sci.* **2022**, *23*, 10230. https://doi.org/10.3390/ijms231810230

Received: 22 August 2022
Accepted: 23 August 2022
Published: 6 September 2022

Product	Molecular Weight (kDa)	Particle Size (nm) [39]	Zeta Potential (mV) [39]	Crystalline Structure	Reduction Potential (mV) ° [25]	Reduction Kinetics $k(\Theta) \times 10^3$ (min^{-1}) Θ = 0.1/0.5/0.8 [25]	Blocking Temperature (K) [25,40]
Iron sucrose	34–60 [17,41] 42–44 [25] 252 [42] 140 [39]	8.3 (PDI 0.192)	pH 7.43: −26.20 pH 11.03 *: −28.15	2-line ferrihydrite [39] Ferrihydrite and lepidocrocite [41] Akageneite [33] 2-line ferrihydrite-like [40] No clear identification [25]	−494	107/89/117 §	55
Sodium ferric gluconate	289–440 [18] 37.5 [9] 200 [42] 164 [39]	8.6 (PDI 0.244)	pH 7.4: −29.70 pH 8.36 *: −29.10	2-line ferrihydrite ([39] Ferrihydrite and lepidocrocite [41] Akaganeite [33]	nd	nd	nd
Iron dextran	165 [20] 165 [39]	12.2 (PDI 0.149)	pH 6.4 *: −15.30 pH 7.31: −17.25	Akageneite [39,41]	nd	nd	nd
Ferric derisomaltose	155[22] 63–69 [25] 150 [39]	9.9 (PDI 0.182)	pH 6.3 *: −22.0 pH 7.35: −21.05	Akaganeite [25,39,41]	−338/−508	21/41/63	56
Ferric carboxymaltose	≈ 150 [24] 145–155 [25] 233 [39]	23.1 (PDI 0.07)	pH 5.36: 3.68 pH 7.26: −8.52	Akaganeite [25,39,41]	−333	18/35/55	114
Ferumoxytol	750 [26] 172–188 [25] 731 [42] 276 [39]	23.6 (PDI 0.143)	pH 6.6: −43.20 pH 7.36: −30.55	Magnetite/ Maghemite [39] Magnetite [41] Maghemite [25]	−245/−768	36/67/98	73

Reference

1. Funk, F.; Flühmann, B.; Barton, A.E. Criticality of surface characteristics of intravenous iron-carbohydrate nanoparticle complexes: Implications for pharmacokinetics and pharmacodynamics. *Int. J. Mol. Sci.* **2022**, *23*, 2140. [CrossRef] [PubMed]